FDA Approval Alert: The Need-to-Know | Dordaviprone in H3 K27M-Mutated Diffuse Midline Glioma
In August 2025, the FDA granted accelerated approval to the protease activator dordaviprone as a treatment for pediatric and adult patients who are 1 year or older with H3 K27M-mutated diffuse midline glioma that has progressed after prior therapy.
